PACIFIC BIOSCIENCES CALIF IN's ticker is PACB and the CUSIP is 69404D108. A total of 215 filers reported holding PACIFIC BIOSCIENCES CALIF IN in Q4 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $241,504 | -42.8% | 29,380 | -69.2% | 0.00% | -100.0% |
| Q2 2022 | $422,000 | -52.2% | 95,454 | -1.5% | 0.00% | 0.0% |
| Q1 2022 | $883,000 | +0.3% | 96,953 | +125.3% | 0.00% | 0.0% |
| Q4 2021 | $880,000 | -20.0% | 43,034 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $1,100,000 | +202.2% | 43,034 | +314.0% | 0.00% | – |
| Q2 2021 | $364,000 | -10.1% | 10,395 | -33.2% | 0.00% | -100.0% |
| Q4 2020 | $405,000 | +175.5% | 15,567 | -63.5% | 0.00% | – |
| Q2 2020 | $147,000 | +86.1% | 42,672 | +65.2% | 0.00% | – |
| Q1 2020 | $79,000 | +14.5% | 25,835 | +97.5% | 0.00% | – |
| Q4 2019 | $69,000 | -98.5% | 13,082 | -98.5% | 0.00% | -100.0% |
| Q3 2019 | $4,620,000 | -11.8% | 895,286 | +3.4% | 0.01% | -10.0% |
| Q2 2019 | $5,239,000 | +9784.9% | 865,958 | +6158.7% | 0.01% | – |
| Q4 2016 | $53,000 | – | 13,836 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,660,000 | $24,206,000 | 11.49% |
| Data Collective II GP, LLC | 164,249 | $1,495,000 | 5.44% |
| Decheng Capital Management III (Cayman), LLC | 1,463,872 | $13,321,000 | 4.08% |
| SB Management Ltd | 1,886,107 | $17,164,000 | 3.33% |
| Casdin Capital, LLC | 7,990,652 | $72,715,000 | 3.26% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,225,395 | $11,151,000 | 2.20% |
| Jackson Square Partners, LLC | 22,542,589 | $205,137,000 | 2.04% |
| BOURNE LENT ASSET MANAGEMENT INC | 556,865 | $5,067,000 | 1.59% |
| ARK Investment Management | 27,259,521 | $248,062,000 | 1.04% |
| Nikko Asset Management Americas, Inc. | 14,021,205 | $127,873,000 | 0.94% |